Skip to contentM
Madrigal Pharmaceuticals, Inc.
M
MDGLMadrigal Pharmaceuticals, Inc. Released Nov 14, 2016, after the close
10-Q filed Nov 14, 2016, 45 days after period end · 0001104659-16-156989
Q3 2016 · 10-Q
Revenue—
Net Income-$14.05M-$14.05Mderivedno prior Q3 2015 on fileno prior Q2 2016 on file EPS Diluted-$1.59-$1.59
No earnings release is on file for this quarter. Its figures came with the 10-Q.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Madrigal Pharmaceuticals, Inc. · CIK 1157601 · Engraved from SEC EDGAR
N/M vs Q2 2016
Operating Income-$14,091,000N/M Operating Cash Flowderived-$9,243,000N/M ended Sep 30, 2016 · filed Nov 14, 2016 · 45 d after period end